JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
There are no items in your shopping cart
Featured Products
Axon 3846
CAS [1358099-18-9]
MF C26H31N7OMW 457.57
C25-140 is a first-in-class TRAF6–Ubc13 inhibitor which reduces TRAF6–Ubc13 activity both in vitro and in cells. C25-140 impedes NF-κB activation in various immune and inflammatory signaling pathways also in primary human and murine cells. Moreover, C25-140 ameliorated inflammation and improved disease outcomes of autoimmune psoriasis and rheumatoid arthritis in preclinical in vivo mouse models.
Keywords: C25-140 | Supplier | TRAF6–Ubc13 inhibitor | C 25-140 | C-25-140 | CAS [1358099-18-9] | NF-κB pathway | Ubiquitin Ligase (E3; other) | Inhibitor | Enzymes | Autoimmune disease | NF receptor-associated factor 6 | Psoriasis | Rheumatoid arthritis
1-(4-Benzylpiperidin-1-yl)-3-(3,5-dimethyl-1-(3-methyl-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazol-4-yl)propan-1-one
[1358099-18-9]
The purity of Axon Ligands™ is confirmed by HPLC-MS, 1H-NMR and/or microanalysis. Analytical data are available upon request.
Caution: Axon Ligands™ are not fully tested. They are for research purposes only! Not for human consumption!
* Required Fields